
SERA
Sera Prognostics Inc.
$2.13
+$0.06(+3.11%)
54
Overall
60
Value
54
Tech
50
Quality
Market Cap
$139.69M
Volume
84.20K
52W Range
$1.37 - $4.09
Target Price
$5.00
Company Overview
| Mkt Cap | $139.69M | Price | $2.13 |
| Volume | 84.20K | Change | +3.11% |
| P/E Ratio | -4.4 | Open | $2.27 |
| Revenue | $81.0K | Prev Close | $2.07 |
| Net Income | $-31.9M | 52W Range | $1.37 - $4.09 |
| Div Yield | N/A | Target | $5.00 |
| Overall | 54 | Value | 60 |
| Quality | 50 | Technical | 54 |
No chart data available
About Sera Prognostics Inc.
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Sector: Industrials
Industry: Research and Development in Biotechnology
Latest News
Sera Prognostics Balances Cash Strength With Slow Ramp
TipRanks Auto-Generated Newsdesk•19 days ago
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Gilead Sciences (GILD) and Sera Prognostics (SERA)
Catie Powers•19 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SERA | $2.13 | +3.1% | 84.20K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |